Piramal Pharma PPLPHARMA
Global CDMO (Piramal Pharma Solutions), complex hospital generics (inhaled anaesthetics, intrathecal therapies) and India consumer health
Mapped in 1 theme: Pharmaceuticals.
Where Piramal Pharma sits in the supply chain
Piramal Pharma appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › Sterile injectables & fill-finish
Direct supplierOther companies in this layer
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 8,171 | 9,151 | 8,869 |
| Net profit | 18 | 91 | −326 |
Latest-year revenue ₹8,869 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Integrated CDMO network in India, UK and North America with ADC and high-potency capability
- Piramal Critical Care is a top inhaled-anaesthetics supplier worldwide
Risks
- FY26 net loss of ₹326 Cr as CDMO customers destocked
- Leverage and very low ROCE
- Customer-specific inventory cycles make earnings lumpy
Common questions
What does Piramal Pharma do?
Global CDMO (Piramal Pharma Solutions), complex hospital generics (inhaled anaesthetics, intrathecal therapies) and India consumer health.
Where does Piramal Pharma sit in the supply chain?
Piramal Pharma (NSE: PPLPHARMA) is mapped in 2 supply-chain layers: Sterile injectables & fill-finish (Pharmaceuticals) and CDMO & contract research (Pharmaceuticals).
Who are Piramal Pharma's peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Anthem Biosciences, Cohance Lifesciences, Laurus Labs and 4 more.
What is Piramal Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹31,832 Cr, ROCE 2.5%, ROE −3.8%, dividend yield 0%.